Tata Power's arm Tata Power Renewable Energy has signed a memorandum of understanding (MoU) with the government of Andhra Pradesh to collab...

Mauritius-based Beige Ltd has sold partial stake in Mankind Pharma through bulk deals on Tuesday. The investors have sold about 1.44 crore ...

The Nifty 50 has risen nearly 4% over the past six sessions. Corporate earnings, scheduled from Tuesday, will be the near-term trigger for ...

"This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceutica...

The US Food and Drug Administration (USFDA) issued form 483 with 15 observations to the company’s Jadcherla Unit

BSE’s Healthcare index has jumped by 4 per cent in the last five trading sessions.

USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection.

Around 5% of the total market share of highway tyres is being served by Balkrishna Industries.

At 2.5 times price to book value FY18, RBL appears attractive and we recommend this for a target of Rs 390 in next 6-9 months, says the HoR...

The stock hit a 52-week high of `700 on Wednesday after the company announced that it has received FDA nod for its generic cancer treatment...

The company has potential to throw many positive surprises on back of pipeline of work that it has done in past few years, according to ana...

Diwan believes that Ipca Labs is at the cusp of a turnaround. He likes Ranbaxy, Cipla and Dr Reddy’s Labs among the largecap names.

Investors lapped up shares of mid-cap pharma firms on Wednesday as weakness in the broader market prompted them to focus on these bets.

Pharma stocks have become laggards of late, given their high valuations, regulatory issues and overall slowdown in sales.

In an interaction with ET Now, Vishnukant Bhutada, Managing Director, Shilpa Medicare, analyses the company’s earnings figures & product ch...

Shilpa Medicare has received the certificate of suitability of Monographs from European Directorate for the Quality of Medicines for the ac...

With anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...